Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma. - Itano T; Huang R; Ozaki T; Nakata E; Fujimura A (Signal transduction and targeted therapy, 2026)